VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer

American Journal of Translational Research

Volumn 5, Issue 3, 2013, Pages 336-346

  Huang, Jianfei ^a,b   Zhang, Jing ^a,c   Li, Hongxia ^a,d   Lu, Zhaohui ^a,e   Shan, Weiwei ^a,f   Mercado Uribe, Imelda ^a   Liu, Jinsong ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NANTONG UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Ovarian cancer; Overall survival; Tumor growth; Vcam1

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; FIBROBLAST; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; RETROVIRUS INFECTION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

EID: 84877077591     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M and Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012; 18: 869-881.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. White KL, Schildkraut JM, Palmieri RT, Iversen ES Jr, Berchuck A, Vierkant RA, Rider DN, Charbonneau B, Cicek MS, Sutphen R, Birrer MJ, Pharoah PP, Song H, Tyrer J, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Phelan CM, Cunningham JM, Fridley BL, Sellers TA and Goode EL. Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res 2012; 72: 1064-1069.
4. Ledermann JA and Raja FA. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer 2011; 47 Suppl 3: S104-115.
5. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD and Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719-725.
6. Fuccio C, Castellucci P, Marzola MC, Al-Nahhas A, Fanti S and Rubello D. Noninvasive and invasive staging of ovarian cancer: review of the literature. Clin Nucl Med 2011; 36: 889-893.
7. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB and Bast RC Jr. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64: 1655-1663.
8. Malhotra S and Kincade PW. Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells. Exp Hematol 2009; 37: 19-30.
9. Yamada Y, Arao T, Matsumoto K, Gupta V, Tan W, Fedynyshyn J, Nakajima TE, Shimada Y, Hamaguchi T, Kato K, Taniguchi H, Saito Y, Matsuda T, Moriya Y, Akasu T, Fujita S, Yamamoto S and Nishio K. Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci 2010; 101: 1886-1890.
10. Galkina E and Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2292-2301.
11. Carter RA and Wicks IP. Vascular cell adhesion molecule 1 (CD106): a multifaceted regulator of joint inflammation. Arthritis Rheum 2001; 44: 985-994.
12. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr and Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159-2166.
13. Holubec L Jr, Topolcan O, Finek J, Holdenrieder S, Stieber P, Pesta M, Pikner R, Holubec Sen L, Sutnar A, Liska V, Svobodova S, Visokai V and Kormunda S. Markers of cellular adhesion in diagnosis and therapy control of colorectal carcinoma. Anticancer Res 2005; 25: 1597-1601.
14. Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A and Kemona H. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res 2012; 129: e47-50.
15. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR and Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensivestage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27: 6006-6011.
16. Coskun U, Sancak B, Sen I, Bukan N, Tufan MA, Gulbahar O and Sozen S. Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages. Int Immunopharmacol 2006; 6: 672-677.
17. Syrigos KN, Salgami E, Karayiannakis AJ, Katirtzoglou N, Sekara E and Roussou P. Prognostic significance of soluble adhesion molecules in Hodgkin's disease. Anticancer Res 2004; 24: 1243-1247.
18. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L and Fayad L. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 2012; 53: 50-56.
19. Kamezaki S, Kurozawa Y, Iwai N, Hosoda T, Okamoto M and Nose T. Serum levels of soluble ICAM-1 and VCAM-1 predict pre-clinical cancer. Eur J Cancer 2005; 41: 2355-2359.
20. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED and Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 2009; 69: 1469-1476.
21. Heidemann J, Maaser C, Lugering A, Spahn TW, Zimmer KP, Herbst H, Rafiee P, Domschke W, Krieglstein CF, Binion DG and Kucharzik TF. Expression of vascular cell adhesion molecule-1 (CD 106) in normal and neoplastic human esophageal squamous epithelium. Int J Oncol 2006; 28: 77-85.
22. Hemmerlein B, Scherbening J, Kugler A and Radzun HJ. Expression of VCAM-1, ICAM-1, E-and P-selectin and tumour-associated macrophages in renal cell carcinoma. Histopathology 2000; 37: 78-83.
23. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Haffty BG, Pantel K, Massague J and Kang Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha-4beta1-positive osteoclast progenitors. Cancer Cell 2011; 20: 701-714.
24. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I and Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 2006; 103: 16472-16477.
25. Yang G, Xiao X, Rosen DG, Cheng X, Wu X, Chang B, Liu G, Xue F, Mercado-Uribe I, Chiao P, Du X and Liu J. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res 2011; 17: 2181-2194.
26. Ngan HY, Odicino F, Maisonneuve P, Creasman WT, Beller U, Quinn MA, Heintz AP, Pecorelli S and Benedet JL. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1: S193-203.
27. Camp RL, Dolled-Filhart M and Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
28. Young T, Mei F, Liu J, Bast RC Jr, Kurosky A and Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene 2005; 24: 6174-6184.
29. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J. Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 2010; 102: 812-827.
30. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB and Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010; 16: 3875-3886.
31. Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A and Bowtell DD. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res 2012; 72: 4060-4073.
32. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD and Matulonis UA. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012; 18: 5806-5815.